326
Views
39
CrossRef citations to date
0
Altmetric
Original Research

Novel silk fibroin nanoparticles incorporated silk fibroin hydrogel for inhibition of cancer stem cells and tumor growth

, , , , , & show all
Pages 5405-5418 | Published online: 17 Sep 2018

Abstract

Background

A multi-drug delivery platform is needed as the intra-tumoral heterogeneity of cancer leads to different drug susceptibility. Cancer stem cells (CSCs), a small population of tumor cells responsible for tumor seeding and recurrence, are considered chemotherapy-resistant and have been reported to be sensitive to salinomycin (Sal) instead of paclitaxel (Ptx). Here we report a novel silk fibroin (SF) hydrogel-loading Sal and Ptx by incorporating drug-loaded silk fibroin nanoparticles (SF-NPs) to simultaneously kill CSCs and non-CSCs.

Methods

Using the method we have previously reported to prepare Ptx-loaded SF-NPs (Ptx-SF-NPs), Sal-loaded SF-NPs (Sal-SF-NPs) were fabricated under mild and non-toxic conditions. The drug-loaded SF-NPs were dispersed in the ultrasound processed SF solution prior to gelation.

Results

The resulting SF hydrogel (Sal-Ptx-NP-Gel) retained its injectable properties, exhibited bio-degradability and demonstrated homogeneous drug distribution compared to the non-NP incorporated hydrogel. Sal-Ptx-NP-Gel showed superior inhibition of tumor growth compared to single drug-loaded hydrogel and systemic dual drug administration in the murine hepatic carcinoma H22 subcutaneous tumor model. Sal-Ptx-NP-Gel also significantly reduced CD44+CD133+ tumor cells and demonstrated the least tumor formation in the in vivo tumor seeding experiment, indicating superior inhibition of cancer stem cells.

Conclusion

These results suggest that SF-NPs incorporated SF hydrogel is a promising drug delivery platform, and Sal-Ptx-NP-Gel could be a novel and powerful locoregional tumor treatment regimen in the future.

Introduction

Hydrogel systems applied in cancer therapy are aimed to locoregionally eradicate tumors by local drug delivery with limited systemic toxicity.Citation1,Citation2 However, tumor heterogeneity has been reported as one of the major obstacles in cancer therapy.Citation3Citation5 The intra-tumoral differences in the genetic and pathological backgrounds of cancer cells leads to differences in drug susceptibility.Citation4 More importantly, cancer stem cells (CSCs), that possess the capacity of self-reproduction, self-renewal and unlimited growth, are only a small fraction of tumor cells, but they are considered to be the root cause of tumor recurrence.Citation6,Citation7 Unfortunately, studies have shown that CSCs are resistant to most anticancer drugs which were designed to kill non-CSC cancer cells.Citation8,Citation9 Thus, dual- or multi-drug delivery platforms designed to target both CSCs and non-CSC cancer cells are desirable.

Salinomycin (Sal), an antibiotic potassium ionophore, has been demonstrated as an effective CSC-specific inhibitor.Citation10Citation12 Sal not only inhibited cancer cells of various cell types with stem cell markers and the tumor sphere formation in vitro but also demonstrated anti-tumor efficacy in vivo. Sal inhibited CSCs by interfering with the Akt signaling pathway, Wnt/β-catenin, Hedgehog and Notch pathways.Citation12 Although clinical pilot studies have been conducted, Sal currently has a narrow therapeutic window as a commonly used veterinary antibiotic.Citation13 Sal poisoning is fatal and is without any effective antidote.Citation14 Therefore, we hypothesized that the locoregional and controlled delivery of Sal could be safer and more efficient.

Traditional chemotherapy has been reported to promote cancer stemness by chemotherapy-induced senescence.Citation15 Several studies have reported that paclitaxel (Ptx) enriched CSCs with the overexpression of CSC surface markers or CSCs associated pathways and low expression of EMT-associated E-cadherin.Citation10,Citation16,Citation17 Sal has shown notable activity against Ptx-resistant CSCs.Citation10 Furthermore, studies have shown that Sal sensitized antimitotic drug Ptx.Citation18Citation20 Thus, co-delivery of Sal and Ptx could be an effective local treatment.

The biocompatibility of hydrogels is as important as effectiveness for future clinical use.Citation1 Silk fibroin (SF) has been proved to be a biocompatible native biomolecule and has a safe record in vivo.Citation21,Citation22 Although chemically cross-linked SF hydrogels have tunable elasticity and other mechanical properties,Citation23,Citation24 ultrasound induced physically cross-linked SF hydrogels have the advantage of injectability as well as biocompatibility and safety without any toxic initiators or cross-linkers.Citation25,Citation26 Additionally, SF hydrogel could be loaded with doxorubicin, and effectively inhibit primary breast cancer in a mouse model.Citation27 Although SF hydrogel containing SF NPs which is loaded with hydrophilic dyes has been reported,Citation28 the development of new strategies to load SF hydrogel with hydrophobic cancer therapeutic drugs, such as Sal and Ptx, are desired.

We have recently reported a novel and non-toxic method to prepare Ptx-loaded silk fibroin nanoparticles (Ptx-SF-NPs).Citation29,Citation30 In this study, we successfully prepared Sal-loaded silk fibroin nanoparticles (Sal-SF-NPs) by using a similar method. We fabricated the silk fibroin hydrogel-loading hydrophobic drugs based on nanoparticle dispersion. The present investigation outlines the characterization of nanoparticles and hydrogels, and the toxicity, anti-tumor efficacy and inhibition of CSCs.

Materials and methods

Materials

Cocoons of Bombyx mori silkworm were procured from Jiangsu Province, China. Sal was provided by the China Institute of Veterinary Drugs Control (Beijing, China). Ptx was provided by the Jiangsu Yew Pharmaceutical Co., Ltd (Jiangsu, China). Ptx injection was provided by the Yangtze River Pharmaceutical Group (Jiangsu, China). Protease XIV (Sigma-Aldrich Co., St Louis, MO, USA), 2,4-dinitrophenyl-hydrazine (Sigma-Aldrich, USA), anti-human/mouse CD44 APC (eBioscience, Inc., San Diego, CA, USA), and anti-mouse CD133 PE (eBioscience Inc.) were used as received. Acetonitrile (EMD Millipore, Billerica, MA, USA) and methanol (EMD Millipore) were of HPLC grade. Milli-Q ultra-pure water was used. Anhydrous calcium chloride, absolute ethanol and other chemicals were of analytical grade and used without further purification. Murine hepatic carcinoma cell line H22 was purchased from the Shanghai Institute of Cell Biology (Shanghai, China).

Silk fibroin extraction and purification

The SF aqueous solution was prepared as previously reported.Citation29 Briefly, the cocoons were cut into small pieces and degummed for 30 minutes twice in boiled 0.5% sodium carbonate followed by thorough washing with deionized water. The degummed SF was dissolved in a ternary solution (molar ratio CaCl2/CH3CH2OH/H2O=1:2:8) at 70°C for 4 hours. The resulting solution was dialysed (molecular weight cut-off [MWCO] 14,000 Da) against ultra-pure water for 4 days to remove salts and ethanol. After centrifugation (10,000 rpm for 15 minutes) to spin down the debris and filtration through a 0.22-µm filter for sterilization, the SF aqueous solution (50 mg/mL) was stored at 4°C and diluted with sterilized Milli-Q water prior to use. The concentration of SF solution was determined by weighing the residual solid after drying at 50°C for 24 hours.

Sal-loaded silk fibroin nanoparticle preparation

Sal-SF-NPs were prepared in aqueous solution under ambient temperature. Sal dissolved in ethanol was introduced drop-wise into 15 mg/mL SF solution under constant stirring. The resulting milky bluish solution was filtered and centrifuged at 12,000 rpm for 45 minutes. The pellets were washed twice and re-suspended in saline by using an ultrasound processor SONICS Vibra-cell VCX130 (Sonics & Materials, Inc., Newtown, CT, USA) at 20% amplitude for 2 seconds. Ptx-SF-NPs were prepared as previously reported.Citation29

Nanoparticle characterization

Particle size and ζ potential

Sal-SF-NPs particle size and polydispersity (PDI) were measured in triplicate by dynamic light scattering (DLS) with the Brookhaven BI-900AT instrument (Brookhaven Instruments Corporation, Holtsville, NY, USA) at 25°C. The ζ potential was determined in octuplet by a ζ potential analyzer (Brookhaven Instruments Corporation, USA).

Morphology study

The morphological study of Sal-SF-NPs was conducted under-JEM-1011 (Japan) transmission electron microscopy (TEM). Copper wire meshes were immersed in the Sal-SF-NP aqueous solution for seconds and air-dried prior to observation without staining.

Infrared spectra and X-ray diffraction

To investigate the conformation of SF in Sal-SF-NPs, infrared spectra were recorded with a Fourier transform infrared spectrophotometer (FTIR) (Bruker VERTEX 80V, Ettlingen, Germany). Lyophilized regenerated silk fibroin (LSF) and degummed silk fibroin fiber (SFF) were also examined. The spectra were all recorded at a resolution of 4 cm−1 and were generated from 64 scans. To determine the β-sheet structure and crystallinity of SF in Sal-SF-NPs, the X-ray diffraction (XRD) intensity curves were measured by a Rigaku Ultima III X-ray diffractometer (Rigaku Corporation, Tokyo, Japan). LSF and SFF were also examined. The curves were all recorded at a scanning rate of 3°/min with the scanning region of 3°–45°.

Drug loading content and encapsulation efficiency

The drug loading content and encapsulation efficiency of Sal-SF-NPs were analyzed by the Agilent HPLC system with a Zorbax C18 column (150×4.6 mm, 5 µm, Agilent Technologies, Santa Clara, CA, USA) by using a pre-column derivatization method.Citation31 Briefly, samples were dissolved in 700 µL of methanol and a volume of 200 µL of trichloroacetic acid aqueous solution was added to each sample. After adding 100 µL of 2,4-dinitrophenyl-hydrazine (DNP), the samples were incubated at 55°C for 30 minutes followed by HPLC. The mobile phase was methanol/1.5% aqueous acetic acid (90/10, v/v). The retention time for Sal was 16.3 minutes at 362 nm detection wavelength. The drug loading and encapsulation were assessed by HPLC for three independent batches of NPs. The drug loading content (DL) and encapsulation efficiency (EE) were calculated by the following equations:

DL%=WeightofthedruginNPsWeightofNPs×100%
EE%=WeightofthedruginNPsWeightofthefeedingdrug×100%.

Sal-Ptx-NP-Gel preparation

Ultrasound induced silk fibroin hydrogel was prepared as reported with mild modifications.Citation25 Briefly, 1 mL SF aqueous solution in a 1.5 mL Eppendorf tube was sonicated with an ultrasonic processor Sonics Vibra-Cell™ VCX 130 (Sonics & Materials, Inc.) at 60% amplitude for 1 minute. After the solution was cooled to room temperature within 3 minutes, Sal-SF-NPs and Ptx-SF-NPs were dispersed in the solution with the ultrasound processor at 20% amplitude for 2 seconds to prepare the Sal-Ptx-NP-Gel. For the injectable hydrogel formulation and drug loading homogeneity study, the sonicated solution was aspirated into a 1 mL syringe and incubated vertically at 60°C for 1 hour to ensure the sol-gel transition. For the swelling study, in vitro degradation study and in vitro drug release studies, 500 µL of the sonicated solution was pipetted onto a Millicell insert (Millipore PCF 3 µm) and incubated for gel formation. For Sal-Ptx-non-NP-Gel, powder of pristine Sal and Ptx, instead of drug-loaded SF NPs, was dispersed in the sonicated solution at 30% amplitude for 5 seconds.

Hydrogel characterization

Infrared spectra and X-ray diffraction

To investigate the conformation of SF in the Ptx-Sal-NP-Gel, spectra of FTIR and XRD were recorded with the same parameter settings as reported above. Lyophilized blank SF hydrogel (Gel) and Ptx-Sal-non-NP-Gel were also examined.

Swelling study

To study the swelling property of SF hydrogel, hydrogels in Millicell inserts were incubated in 4 mL of 0.01 M PBS, pH 7.4, at 37°C. At predetermined time points, the inserts were collected and blotted to remove excess water on the gel surface, and subsequently weighed. The swelling ratio (SR) was calculated by the following equation:

SR=GelweightInitialgelweight.

In vitro degradation study

To study the in vitro degradation of SF hydrogel, hydrogel in Millicell inserts was incubated in 4 mL of Protease XIV solution (2.5 units per 5 mg SF) at 37°C. The control hydro-gel was placed in 4 mL of PBS. The solutions were replaced every 4 days. At the indicated times, the inserts were collected and photographed.

Drug-loading homogeneity study

To determine the drug-loading homogeneity of nanoparticles incorporated hydrogel, Sal-Ptx-NP-Gel and Sal-Ptx-non-NP-Gel were prepared in 1 mL syringes, which were vertically placed during the sol-gel transition so that the insoluble drug particles aggregated and gathered in the lower region of the syringe. A volume of 0.2 mL of hydrogel was successively injected from the syringe to obtain five samples from different parts of the syringes, labelled part 1, 2, 3, 4 and 5 of the hydrogel. The samples were dried, followed by drug content determination using HPLC. Sal was quantified as described above in ‘Drug loading content and encapsulation efficiency’. For Ptx quantification, the mobile phase was acetonitrile/water (52/48, v/v). The retention time for PTX was 5.5 minutes at a 227 nm detection wavelength. The relative drug content (RDC) of each part of the hydrogel was calculated by the following equation:

RDC=DrugweightAveragedrugweightofthefiveparts

Average drug weight was calculated as the average of all of the five samples. The drug loading homogeneity was assessed by three independent batches of Sal-Ptx-NP-Gel and Sal-Ptx-non-NP-Gel.

In vitro drug release study

To determine the drug release pattern from SF hydrogel, Ptx-NP-Gel and Sal-NP-Gel were prepared in Millicell inserts. For Ptx release, the inserts were placed in 8 mL of PBS buffer with 0.5% Tween80. For Sal release, the inserts were immersed into 4 mL PBS. Release buffers were replaced at indicated times. The drug content in the release buffer was determined by HPLC as described above.

In vivo toxicity study of Sal-Ptx-NP-Gel

The animal experiments were approved by the Animal Care Committee at Drum Tower Hospital, Nanjing, China. Healthy drug naïve male ICR mice with body weight of 25±2 g were raised under a specific pathogen-free (SPF) environment in compliance with the guidelines set by the committee. For the in vivo toxicity study, the mice were randomly divided into six groups; and each group contained three mice. On day 1, six groups of mice were treated with Sal solution (2 mg/kg, intraperitoneal injection [IP]), Sal solution (4 mg/kg, IP), Sal solution (2 mg/kg, subcutaneous injection [IH]), Sal solution (4 mg/kg, IH), Sal-Ptx-NP-Gel (2 mg/kg Sal, IH) and Sal-Ptx-NP-Gel (4 mg/kg Sal, IH), respectively. Survival were observed. On days 7, 14 and 28, the mice in the group treated with Sal-Ptx-NP-Gel (4 mg/kg Sal, IH) were sacrificed. Heart, liver, and skeletal muscle samples were collected for H&E staining.

In vivo tumor and cancer stem cells inhibition study

In vivo antitumor efficacy

The animal experiments were approved by the Animal Care Committee at Drum Tower Hospital, Nanjing, China. To investigate the in vivo anti-tumor efficacy of Sal-Ptx-NP-Gel, a subcutaneous murine hepatic cancer H22 tumor-bearing mouse model was used. Healthy drug naïve male ICR mice weighing of 20±2 g were raised under an SPF environment in compliance with the guidelines set by the committee. A volume of 0.2 mL of saline containing 2×106 H22 cells was subcutaneously injected into the lower right axilla of the mice. When the tumors reached 100–300 mm3 in volume, the mice were randomly divided into eight groups with each group comprising six mice. The day was marked as “Day 1”. On day 1, eight groups were treated with normal saline (NS), blank SF gel, Ptx injection (18 mg/kg Ptx, intravenous injection [IV]), Sal solution (2 mg/kg/d Sal, IP, day 1 and 2), Ptx injection with Sal solution (18 mg/kg Ptx, IV; 2 mg/kg/d Sal, IP, day 1 and 2), Ptx-NP-Gel (18 mg/kg Ptx, peritumoral injection [PT]), Sal-NP-Gel (4 mg/kg Sal, PT) and Sal-Ptx-NP-Gel (18 mg/kg Ptx and 4 mg/kg Sal PT), respectively. Tumor sizes were measured daily by Vernier calipers, and the tumor volumes were calculated as V=D×d2/2 (D and d were the longest and the shortest diameter of tumor in mm, respectively). Relative tumor volumes were calculated by the following equation to reduce the impact of initial tumor volume differences after grouping:

Relativetumorvolume=VV0
where: V was the absolute tumor volume, and V0 was the average tumor volume of the group on Day 1. On day 7, the mice were sacrificed. Tumors were collected for pathological study by H&E staining.

Flow cytometry of cancer stem cells

Each tumor from groups treated with saline, Ptx-NP-Gel, Sal-NP-Gel and Sal-Ptx-NP-Gel was minced, filtered through a 200-mesh sieve, washed with saline and re-suspended in saline to make single cell suspensions for further experiments. The ratio of CD44+CD133+ cancer stem cells in the single cell suspensions was investigated by a flow cytometry (BD FACS Aria II, BD Biosciences, San Jose, CA, USA). The randomly selected three samples from each group were incubated with anti-human/mouse CD44 allophycocyanin and anti-mouse CD133 PE for 15 minutes at the manufacturer’s recommended concentration. After washing twice with saline, the cell suspensions were analyzed by flow cytometry.

Tumor seeding study

To investigate the tumor seeding ability of the tumors after treatment, the single cell suspensions were re-injected into healthy male ICR mice to monitor tumor formation. In each group, three samples of the single cell suspensions were mixed and counted for cell concentration. A volume of 0.2 mL of saline containing 106, 104 or 103 cells was subcutaneously injected into lower right axilla of the mice. Tumor incidence was monitored for 45 days after injection, and tumor formation was assayed by palpation. In the group of 106 cells, tumor sizes were measured and survival was monitored.

Statistical analysis

The data are listed as the means ± SD except the DLS, ζ potential and animal experiments, where data are listed as the means ± SEM. Statistical analysis of the data was made by ANOVA, Student’s t-test or the Mann–Whitney U test. P<0.05 was considered significantly different.

Results

Fabrication and characterization of Sal-loaded silk fibroin NPs

Sal-SF-NPs were fabricated by using a method similar to that used to prepare Ptx-SF-NPs. The SF aqueous solution turned milky after introducing Sal ethanol solution (, right), while no obvious change was observed by adding an equivalent volume of ethanol without Sal (, left). The self-assembling Sal-SF-NPs were round shaped under TEM with a dense core and a thin corona (). The average diameter of Sal-SF-NPs under TEM was approximately 120 nm (). The DLS hydrodynamic diameter and ζ potential varied with SF concentration instead of drug feeding (). The SF concentration of 15 mg/mL and Sal feeding of 6 mg were selected for the next experiment. The drug loading and encapsulation efficiency of Sal-SF-NPs were 12.1%±2.3% and 34.7%±1.0%, respectively.

Table 1 Characterization of Sal-SF-NPs fabricated by different silk concentrations and drug feedings

Figure 1 Fabrication and characterization of Sal-SF-NPs.

Notes: (A) The formation of Sal-SF-NPs. Right, SF solution adding Sal ethanol solution. Left, SF solution adding equivalent ethanol. (B) TEM of Sal-SF-NPs. (C) FTIR of Sal-SF-NPs. (D) XRD of Sal-SF-NPs. SFF and LSF were recorded as controls for silk II and silk I conformation, respectively.

Abbreviations: Sal, salinomycin; SF, silk fibroin; NPs, nanoparticles; FTIR, Fourier transform infrared spectroscopy; TEM, transmission electron microscopy; XRD, X-ray diffraction; SFF, silk fibroin fiber; LSF, lyophilized regenerated silk fibroin.

Figure 1 Fabrication and characterization of Sal-SF-NPs.Notes: (A) The formation of Sal-SF-NPs. Right, SF solution adding Sal ethanol solution. Left, SF solution adding equivalent ethanol. (B) TEM of Sal-SF-NPs. (C) FTIR of Sal-SF-NPs. (D) XRD of Sal-SF-NPs. SFF and LSF were recorded as controls for silk II and silk I conformation, respectively.Abbreviations: Sal, salinomycin; SF, silk fibroin; NPs, nanoparticles; FTIR, Fourier transform infrared spectroscopy; TEM, transmission electron microscopy; XRD, X-ray diffraction; SFF, silk fibroin fiber; LSF, lyophilized regenerated silk fibroin.

To investigate the conformation of SF in Sal-SF-NPs, FTIR spectra () and XRD () were recorded. In IR spectra, SFF with a typical silk II structure comprising β-sheets had characteristic absorption bands at 1,620 (amide I), 1,507 (amide II), 1,229 (amide III), and 1,064 cm−1 (amide IV). LSF with mainly silk I structure composed of α-helices and random coils had absorption frequencies at 1,642 (amide I), 1,514 (amide II), 1,228 (amide III), and 1,066 cm−1 (amide IV). Sal-SF-NPs had absorption at 1,647 (amide I), 1,516 (amide II) and 1,240 cm−1 (amide III), which were shifted from β-sheets structure, indicating a silk I or random coil conformation. Additional peaks at 1,113 and 1,039 cm−1 instead of amide IV in Sal-SF-NPs were characteristic of Sal encapsulated in NPs, confirmed by pristine Sal IR spectrum. In XRD, the characteristic diffraction peaks of β-sheets crystalline at 2θ=20.19° were observed in SFF. For LSF and Sal-SF-NPs, no obvious peak was detected at 2θ=20.19°, which was consistent with IR results showing that random coils instead of β-sheets were the conformation of SF in Sal-SF-NPs. The intensive peaks of pristine Sal were not obvious in Sal-SF-NPs, which proved that Sal was encapsulated in the NPs in an amorphous state.

Preparation and characterization of Sal-Ptx-NP-Gel

Ultrasound-induced SF hydrogel was fabricated by sonicating SF aqueous solution and incubating the sonication processed SF solution (, right) at 60°C for 1 hour. After dispersing the drug-loaded SF-NPs in the sonication-processed solution (, middle) followed by incubation, Sal-Ptx-NP-Gel was prepared (, left). Sal-Ptx-NP-Gel could be injected through a 26G needle from a prefilled syringe (), indicating this gel as a potential minimally invasive treatment. SF hydrogel showed no swelling during a 10-days’ observation (). In vitro degradation study demonstrated that SF hydrogel was biodegradable. While SF hydrogel showed no obvious change in PBS for 21 days, SF hydrogel in protease solution gradually turned transparent with reduced volume (). Incorporating SF-NPs did not change the stability of the hydrogel in PBS as indicated by the drug release study.

Figure 2 Preparation and characterization of Sal-Ptx-NP-Gel.

Notes: (A) Preparation of Sal-Ptx-NP-Gel. Left, sonicated SF solution; Middle, Sal-SF-NPs and Ptx-SF-NPs dispersed in sonicated SF solution; right, formation of Sal-Ptx-NP-Gel. (B) Injectable Sal-Ptx-NP-Gel from a 26G syringe needle. (C) Swelling ratio of SF hydrogel as a function of time. (D) In vitro degradation of SF hydrogel. (E) Schematic plot of drug loading homogeneity study. Syringes containing SF solution were vertically placed during sol-gel transition. Drug contents of five different parts of the hydrogel were determined by HPLC. (F) Relative drug content of five parts in NP-Gel and non-NP-Gel. *P<0.05.

Abbreviations: NS, no significance; Sal, salinomycin; Gel, hydrogel; Ptx, paclitaxel; SF, silk fibroin; NP, nanoparticle.

Figure 2 Preparation and characterization of Sal-Ptx-NP-Gel.Notes: (A) Preparation of Sal-Ptx-NP-Gel. Left, sonicated SF solution; Middle, Sal-SF-NPs and Ptx-SF-NPs dispersed in sonicated SF solution; right, formation of Sal-Ptx-NP-Gel. (B) Injectable Sal-Ptx-NP-Gel from a 26G syringe needle. (C) Swelling ratio of SF hydrogel as a function of time. (D) In vitro degradation of SF hydrogel. (E) Schematic plot of drug loading homogeneity study. Syringes containing SF solution were vertically placed during sol-gel transition. Drug contents of five different parts of the hydrogel were determined by HPLC. (F) Relative drug content of five parts in NP-Gel and non-NP-Gel. *P<0.05.Abbreviations: NS, no significance; Sal, salinomycin; Gel, hydrogel; Ptx, paclitaxel; SF, silk fibroin; NP, nanoparticle.

In IR spectra (), blank SF hydrogel (Gel) had characteristic absorption bands at 1,619 (amide I), 1,514 (amide II), 1,233 (amide III), and 1,063 cm−1 (amide IV), while Sal-Ptx-NP-Gel had absorption frequencies at 1,619 (amide I), 1,514 (amide II), 1,230 (amide III), and 1,066 cm−1 (amide IV). The wavenumber of amide I indicated the β-sheet conformation in Gel and Sal-Ptx-NP-Gel. In the XRD spectrum (), both Gel and Sal-Ptx-NP-Gel had the characteristic diffraction peaks of crystalline β-sheets at 2θ=20.19°. Thus, during the sol-gel transition, SF conformation was transformed from α-helices and random coils to the β-sheets structure.

Figure 3 Characterization of Sal-Ptx-NP-Gel.

Notes: (A) FTIR of Sal-Ptx-NP-Gel. (B) XRD of Sal-Ptx-NP-Gel. (C) In vitro Ptx release from SF hydrogel as a function of time. *P<0.05. (D) In vitro Sal release from SF hydrogel as a function of time.

Abbreviations: FTIR, Fourier transform infrared spectroscopy; Sal, salinomycin; Ptx, paclitaxel; Gel, hydrogel; SF, silk fibroin; NP, nanoparticle; XRD, X-ray diffraction.

Figure 3 Characterization of Sal-Ptx-NP-Gel.Notes: (A) FTIR of Sal-Ptx-NP-Gel. (B) XRD of Sal-Ptx-NP-Gel. (C) In vitro Ptx release from SF hydrogel as a function of time. *P<0.05. (D) In vitro Sal release from SF hydrogel as a function of time.Abbreviations: FTIR, Fourier transform infrared spectroscopy; Sal, salinomycin; Ptx, paclitaxel; Gel, hydrogel; SF, silk fibroin; NP, nanoparticle; XRD, X-ray diffraction.

Drug-loading homogeneity and release pattern

To prove the drug-loading homogeneity of nanoparticle incorporated hydrogel, both drug loading Sal-Ptx-NP-Gel and Sal-Ptx-non-NP-Gel were prepared in 1 mL syringes, which were vertically placed during the sol-gel transition so that the insoluble drug particles aggregated and gathered in the lower part of the syringes (). A volume of 0.2 mL of hydrogel was successively injected out of the syringe to obtain five samples from the different parts of the syringes (). In NP-Gel, there was no significant difference (P>0.05) in the relative drug contents for both Ptx and Sal (), indicating the homogeneity of drug distribution. However, in non-NP-Gel, there was a significant difference (P<0.05) in relative drug contents for both Ptx and Sal (). In addition, the differences of IR and XRD of Sal-Ptx-NP-Gel and Sal-Ptx-non-NP-Gel () demonstrated that the hydrophobic Ptx and Sal were encapsulated in Sal-Ptx-NP-Gel in an amorphous state, which explained the homogeneous drug distribution.

We next investigated the in vitro drug release pattern from SF hydrogel. Ptx was continuously released from the hydrogel for more than 30 days (). The releasing rate was faster in the first 10 days and remained steady in the next 20 days. On day 30, there was significant difference (P<0.05) in the cumulative drug release for different concentrations of SF, indicating that the higher the concentration of SF in the hydrogel the slower the drug release rate. Sal, another hydrophobic drug, showed a different release pattern compared with Ptx (). A burst release was observed and 83.8%±1.7% of Sal was released in the first 9 hours. Subsequently, 94.5%±1.7% of salinomycin was released in 24 hours and 98.3%±0.3% in 5 days. Thus, the drug release pattern of SF hydrogel was mainly dependent on the SF concentration and physicochemical property of the drug.

In vivo toxicity study

The toxicity study showed that Sal-Ptx-NP-Gel increased the maximum tolerated dose of Sal. ICR mice all survived after subcutaneous injection of Sal-Ptx-NP-Gel containing 4 mg/kg Sal above the lethal dose of 2 mg/kg pristine Sal (). Sal-Ptx-NP-Gel with 4 mg/kg Sal was well tolerated, and there was no obvious change in H&E staining of the heart, liver, and skeletal muscles (), indicating the in vivo safety of Sal-Ptx-SF-NPs.

Table 2 Survival of mice after Sal treatment in solution and Gel formation

Figure 4 H&E staining of murine organs after the injection of Sal-Ptx-NP-Gel.

Abbreviations: Sal, salinomycin; Ptx, paclitaxel; NP, nanoparticle; Gel, hydrogel.

Figure 4 H&E staining of murine organs after the injection of Sal-Ptx-NP-Gel.Abbreviations: Sal, salinomycin; Ptx, paclitaxel; NP, nanoparticle; Gel, hydrogel.

In vivo anti-tumor efficacy of Sal-Ptx-NP-Gel

The anti-tumor efficacy of Sal-Ptx-NP-Gel was evaluated on a subcutaneous H22 tumor-bearing ICR mouse model, and the experimental groups included single drug and combination drug regimens by systemic and locoregional administrations (). The combined administration of Ptx injection and Sal solution demonstrated significantly smaller relative tumor size (4.98±0.51) than the single injection of the drug Ptx injection (7.52±0.53) or Sal solution (7.26±0.51) (P<0.05) (). The locoregional administration of Sal-Ptx-NP-Gel showed the smallest tumor size (2.32±0.30), and there was a significant difference (P<0.05) between Sal-Ptx-NP-Gel administration and systemic drug administration (). In addition, hydrogel loading a single drug also exhibited better local tumor control than systemic single drug treatment (), although these treatments were not as effective as the combination drug delivery of the hydrogel Sal-Ptx-NP-Gel. Furthermore, pathological studies of the tumors were conducted as supplements of the tumor size study (). Necrotic areas were the most obvious in the Sal-Ptx-NP-Gel group, which explained the smallest tumor volumes at the pathological level.

Figure 5 Anti-tumor efficacy of Sal-Ptx-NP-Gel.

Notes: (A) Relative tumor volumes after treatment. (B), (C) and (D) are parts of (A) to clearly demonstrate the results. *P<0.05. (E) H&E staining of the tumors.

Abbreviations: Sal, salinomycin; Ptx, paclitaxel; NP, nanoparticle; Gel, hydrogel.

Figure 5 Anti-tumor efficacy of Sal-Ptx-NP-Gel.Notes: (A) Relative tumor volumes after treatment. (B), (C) and (D) are parts of (A) to clearly demonstrate the results. *P<0.05. (E) H&E staining of the tumors.Abbreviations: Sal, salinomycin; Ptx, paclitaxel; NP, nanoparticle; Gel, hydrogel.

Figure 6 Cancer stem cell inhibition of Sal-Ptx-NP-Gel.

Notes: (A), (B), (C) and (D) Flow cytometry detection of CD44+CD133+ cancer stem cells in control, Ptx-NP-Gel, Sal-NP-Gel and Sal-Ptx-NP-Gel groups. (E) CD44+CD133+ cell ratios in each group. *P<0.05 compared with control group. (F) Tumor formation in tumor seeding experiments after primary treatment. (G) Tumor volumes of each group seeded with 106 tumor cells. (H) Survivals of each group seeded with 106 tumor cells.

Abbreviations: Sal, salinomycin; Ptx, paclitaxel; NP, nanoparticle; Gel, hydrogel.

Figure 6 Cancer stem cell inhibition of Sal-Ptx-NP-Gel.Notes: (A), (B), (C) and (D) Flow cytometry detection of CD44+CD133+ cancer stem cells in control, Ptx-NP-Gel, Sal-NP-Gel and Sal-Ptx-NP-Gel groups. (E) CD44+CD133+ cell ratios in each group. *P<0.05 compared with control group. (F) Tumor formation in tumor seeding experiments after primary treatment. (G) Tumor volumes of each group seeded with 106 tumor cells. (H) Survivals of each group seeded with 106 tumor cells.Abbreviations: Sal, salinomycin; Ptx, paclitaxel; NP, nanoparticle; Gel, hydrogel.

In vivo cancer stem cell inhibition of Sal-Ptx-NP-Gel

To investigate the cancer stem cell inhibition of Sal-Ptx-NP-Gel, CD44+CD133+ cell ratios and tumor seeding abilities of group control, Ptx-NP-Gel, Sal-NP-Gel and Sal-Ptx-NP-Gel were evaluated. CD44 and CD133 have been reported as the surface markers of cancer stem cells, including hepatocarci-noma.Citation32 CD44+CD133+ double-positive cells were detected by flow cytometry, and the positive incidence was lower than 1% (). The CD44+CD133+ cell ratio of the Sal-Ptx-NP-Gel group (0.23%±0.03%) was significantly lower than that of the control group (0.44%±0.05%) (P<0.05), while there was no decline in the cancer stem cell ratios in the other two experimental groups (). Thus, Sal-Ptx-NP-Gel treatment decreased the proportion of CD44+CD133+ cancer stem cells.

Cancer stem cell inhibition of Sal-Ptx-NP-Gel was also assessed by a tumor seeding experiment. The results showed that Sal-Ptx-NP-Gel treatment resulted in a 10-fold decrease in tumor-seeding ability relative to the control group (). Furthermore, Sal-Ptx-NP-Gel group demonstrated slower tumor growth compared to any other groups when seeded with 106 cells (P<0.05) () and the longest survival (). These findings indicated that Sal-Ptx-NP-Gel treatment decreased the tumor seeding ability of tumor cells.

Discussion

The use of hydrogel for clinical application is considered safe, biocompatible and effective. In the present study, we developed a dual drug delivery platform which was an SF hydrogel system loaded with Sal-SF-NPs and Ptx-SF-NPs for both CSCs and non-CSCs treatment. The characterization of drug-loaded SF-NPs, hydrogel swelling, in vitro degrad-ability, drug-loading homogeneity, drug release pattern, in vivo toxicity, in vivo anti-tumor efficacy and in vivo CSC inhibition were comprehensively investigated. The Sal-Ptx-NP-Gel exhibited superior local tumor control effect and CSC inhibition efficacy.

SF is a natural bio-macromolecule widely studied as a tissue engineering material because of its excellent biocompatibility. Studies have reported that SF solution spontaneously undergoes a sol-gel transition over a long time.Citation33,Citation34 To control the gelation kinetics or modify physical properties, various methods to prepare SF hydrogel have been reported.Citation23,Citation24,Citation35Citation38 In the present study, sonication-induced hydrogel exhibits no swelling, and is degradable and free of toxic cross-linkers, initiators or any other chemicals. Furthermore, consistent with other studies,Citation26,Citation27,Citation39 the hydrogel has been demonstrated as thixotropic and injectable, facilitating local delivery by minimal invasive operation, which is clinically in demand.

SF hydrogels and nanoparticles have been reported for loading anticancer drugs, including doxorubicin,Citation27,Citation38,Citation40 vincristine,Citation39 cisplatin,Citation41 and 5-fluorouracil.Citation42 However, as a drug depot, which contains a large proportion of water, it was a challenge to load hydrophobic drugs into the SF hydrogel. Directly mixing the SF matrix with hydrophobic drugs, such as curcumin, has been used,Citation43,Citation44 but this strategy might lead to drug-loading heterogeneity in SF hydrogel preparation, as confirmed in the present study. The precipitates of Ptx formed immediately after adding Ptx ethanol solution to SF aqueous solution. Although sonication was used before hydrogel formation in order to form a homogeneous system, the precipitates aggregated during the gelling time and caused heterogeneity of drug concentration. To solve this problem, we developed SF-NPs incorporated SF hydrogel based on a previous study of hydrophobic drug-loading SF-NPs. The resulting Sal-Ptx-SF-Gel exhibited drug-loading homogeneity and was suitable for further experiments. We believe that this dual or multi drug-loading platform could be used to load different drugs for various applications.

The secondary structural change of SF is important for understanding the inter- or intra-molecular force of SF protein. The molecular structure of SF consists of large regions of hydrophobic amino acids (repeated sequences of [Gly−Ala−Gly−Ala−Gly−Ser]n), separated by short hydrophilic regions. The present study demonstrated that SF could encapsulate hydrophobic Sal and self-assemble into nanoparticles with an α-helix or random coil conformation. We also observed the α-helix or random coil structure of Ptx-SF-NPs in a previous study. These results indicated that Sal-SF-NPs and Ptx-SF-NPs have a similar structure and SF could assemble into Silk-I rich nanoparticles when loaded with hydrophobic drugs. Instead of β-sheet formation between the repetitive sequences of the SF molecules, the nanoparticles with dense cores were formed by hydrophobic force between the drug and the repetitive hydrophobic sequences.

Previous studies have reported that the slow and sustained controlled release of the encapsulated doxorubicin from the SF hydrogels depended on the SF concentration.Citation27 In the present study, a similar release pattern was observed in the Ptx release experiment. However, another hydrophobic drug, Sal, was released with an obvious initial burst release, which was a pattern reported in antibodies released from SF hydrogel.Citation45,Citation46 The differences in release were due to the drug property and drug-silk interaction. Although Sal was released faster than Ptx in vitro, SF hydrogel effectively increased the maximum tolerated dose of Sal in vivo. Furthermore, Sal-Ptx-NP-Gel was well tolerated in vivo with low toxicity. Based on the successful toxicity studies, in vivo antitumor studies were performed.

Sal preferentially inhibited cancer stem cells. Previous studies have shown that Sal is at least 100 times more effective than the anti-cancer drug Ptx in killing CSCs.Citation10 In vivo studies demonstrated a comparable inhibition rate between Sal and Ptx, which indicated that the strategy to kill only CSCs was not sufficient for tumor eradication. Thus, strategies to kill both CSCs and non-CSC cancer cells are needed. In the present study, the hydrophobic Sal was encapsulated in SF-NPs and subsequently incorporated into SF hydrogel with Ptx-SF-NPs. We found that combination of Sal and Ptx synergistically enhanced the anti-tumor efficacy, consistent with other studies.Citation15 Sal-Ptx-NP-Gel also decreased CD44+CD133+ cancer stem cell proportion and tumor seeding ability. However, we found that Sal-NP-Gel did not exhibit apparent CSC inhibition at the endpoint of the in vivo experiment. A single dose with relative rapid drug releasing of Sal might be the reason, since it is conceivable that non-CSCs within tumors can give rise to CSCs at a low but significant rate.Citation10,Citation47 The Sal-Ptx-NP-Gel, which released Ptx in a sustained manner, inhibited non-CSCs and maintained the low ratio of CSCs.

The drug delivery platform presented here is proposed to include: 1) a multidrug delivery silk fibroin hydrogel loaded with multiple hydrophobic drugs; 2) a biosafety and biocompatible minimal invasive treatment; and 3) a hydrogel system designed based on tumor homogeneity, as advantages that synergistically inhibit tumor growth through Ptx killing non-CSC cells and Sal killing CSCs. Although the drug distribution and drug penetration of the hydrogel system should be further studied, the present study confirmed SF-NPs incorporated SF hydrogel as an effective drug carrier for Ptx and Sal and its enhanced antitumor efficacy by locoregional drug delivery.

Conclusion

Biocompatible Sal-Ptx-NP-Gel was fabricated without toxic organic solvents and surfactants. The hydrogel showed no swelling, in vitro degradability, drug-loading homogeneity and injectable properties. The drug release pattern primarily depended on the SF concentration and physicochemical property of the drug with sustained Ptx release and relatively rapid Sal release. Sal-Ptx-NP-Gel also increased the maximum tolerated dose of Sal. Furthermore, Sal-Ptx-NP-Gel showed superior anti-tumor efficacy for locoregional tumor treatment and CSC inhibition in vivo. The present study highlighted Sal-Ptx-NP-Gel as a biocompatible multi-drug delivery platform for locoregional chemotherapy, and its potential for further clinical application.

Acknowledgments

The work was supported by The National Key Research and Development Program of China (No 2017YFC1308900), National Natural Science Foundation of China (Nos 81602077, 81672398, 81672367, 81572601, 81472216), Program of Jiangsu Provincial Key Medical Center (No YXZXB2016002), Scientific and Technological Development Program of Nanjing (No 201605012), Natural Science Foundation of Jiangsu Province (Grant no BK20151095) and Nanjing Medical Youth Talent Training Project (No QRX17038). The abstract for the present study was presented at the 2015 ASCO Annual Meeting and published online (see https://meetinglibrary.asco.org/record/109244/abstract).

Disclosure

The authors report no conflicts of interest in this work.

References

  • MerinoSMartínCKostarelosKPratoMVázquezENanocomposite hydrogels: 3D polymer-nanoparticle synergies for on-demand drug deliveryACS Nano2015954686469725938172
  • SepantafarMMaheronnaghshRMohammadiHEngineered hydrogels in cancer therapy and diagnosisTrends Biotechnol201735111074108728734545
  • MarusykAAlmendroVPolyakKIntra-tumour heterogeneity: a looking glass for cancer?Nat Rev Cancer201212532333422513401
  • SenftDLeisersonMDMRuppinERonaiZAPrecision oncology: the road aheadTrends Mol Med2017231087489828887051
  • JoungJGOhBYHongHKTumor heterogeneity predicts metastatic potential in colorectal cancerClin Cancer Res201723237209721628939741
  • RavasioRCeccacciEMinucciSSelf-renewal of tumor cells: epigenetic determinants of the cancer stem cell phenotypeCurr Opin Genet Dev201636929927153353
  • BatlleECleversHCancer stem cells revisitedNat Med201723101124113428985214
  • García-RubiñoMELozano-LópezCCamposJMInhibitors of cancer stem cellsAnticancer Agents Med Chem201616101230123927025655
  • ShibueTWeinbergRAEMT, CSCs, and drug resistance: the mechanistic link and clinical implicationsNat Rev Clin Oncol2017141061162928397828
  • GuptaPBOnderTTJiangGIdentification of selective inhibitors of cancer stem cells by high-throughput screeningCell2009138464565919682730
  • FuYZYanYYHeMSalinomycin induces selective cytotoxicity to MCF-7 mammosphere cells through targeting the Hedgehog signaling pathwayOncol Rep201635291292226718029
  • DewanganJSrivastavaSRathSKSalinomycin: A new paradigm in cancer therapyTumour Biol2017393 1010428317695035
  • NaujokatCSteinhartRSalinomycin as a drug for targeting human cancer stem cellsJ Biomed Biotechnol201220129506581723251084
  • BoehmerleWMuenzfeldHSpringerAHuehnchenPEndresMSpecific targeting of neurotoxic side effects and pharmacological profile of the novel cancer stem cell drug salinomycin in miceJ Mol Med201492888990024770997
  • MilanovicMFanDNYBelenkiDSenescence-associated reprogramming promotes cancer stemnessNature201855376869610029258294
  • LarzabalLEl-NikhelyNRedradoMDifferential effects of drugs targeting cancer stem cell (CSC) and non-CSC populations on lung primary tumors and metastasisPLoS One2013811e7979824278179
  • MaoJSongBShiYShRNA targeting Notch1 sensitizes breast cancer stem cell to paclitaxelInt J Biochem Cell Biol20134561064107323500524
  • ZhangYZhangHWangXThe eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micellesBiomaterials201233267969122019123
  • MuntimaduguEKumarRSaladiSRafeeqiTAKhanWCD44 targeted chemotherapy for co-eradication of breast cancer stem cells and cancer cells using polymeric nanoparticles of salinomycin and paclitaxelColloids Surf B Biointerfaces201614353254627045981
  • KuoSZBlairKJRahimyESalinomycin induces cell death and differentiation in head and neck squamous cell carcinoma stem cells despite activation of epithelial-mesenchymal transition and AktBMC Cancer20121255623176396
  • MaitzMFSperlingCWongpinyochitTBiocompatibility assessment of silk nanoparticles: hemocompatibility and internalization by human blood cellsNanomedicine20171382633264228757180
  • OmenettoFGKaplanDLNew opportunities for an ancient materialScience2010329599152853120671180
  • RaiaNRPartlowBPMcGillMEnzymatically crosslinked silk-hyaluronic acid hydrogelsBiomaterials2017131586728376366
  • SuDYaoMLiuJEnhancing mechanical properties of silk fibroin hydrogel through restricting the growth of β-sheet domainsACS Appl Mater Interfaces2017920174891749828470062
  • WangXKlugeJALeiskGGKaplanDLSonication-induced gelation of silk fibroin for cell encapsulationBiomaterials20082981054106418031805
  • ZhangWWangXWangSThe use of injectable sonication-induced silk hydrogel for VEGF165 and BMP-2 delivery for elevation of the maxillary sinus floorBiomaterials201132359415942421889205
  • SeibFPPritchardEMKaplanDLSelf-assembling doxorubicin silk hydrogels for the focal treatment of primary breast cancerAdv Funct Mater2013231586523646041
  • NumataKYamazakiSNagaNBiocompatible and biodegradable dual-drug release system based on silk hydrogel containing silk nanoparticlesBiomacromolecules20121351383138922471816
  • WuPLiuQLiRFacile preparation of paclitaxel loaded silk fibroin nanoparticles for enhanced antitumor efficacy by locoregional drug deliveryACS Appl Mater Interfaces2013523126381264524274601
  • BianXWuPShaHAnti-EGFR-iRGD recombinant protein conjugated silk fibroin nanoparticles for enhanced tumor targeting and antitumor efficiencyOnco Targets Ther201693153316227313461
  • DusiGGambaVLiquid chromatography with ultraviolet detection of lasalocid, monensin, salinomycin and narasin in poultry feeds using pre-column derivatizationJ Chromatogr A19998351–224324610220924
  • MishraLBankerTMurrayJLiver stem cells and hepatocellular carcinomaHepatology200949131832919111019
  • KimUJParkJLiCStructure and properties of silk hydrogelsBiomacromolecules20045378679215132662
  • MatsumotoAChenJColletteALMechanisms of silk fibroin sol-gel transitionsJ Phys Chem B200611043216302163817064118
  • YucelTCebePKaplanDLVortex-induced injectable silk fibroin hydrogelsBiophys J20099772044205019804736
  • NumataKKatashimaTSakaiTState of water, molecular structure, and cytotoxicity of silk hydrogelsBiomacromolecules20111262137214421517113
  • WuXHouJLiMSodium dodecyl sulfate-induced rapid gelation of silk fibroinActa Biomater2012862185219222406911
  • WuHLiuSXiaoLInjectable and pH-responsive silk nanofiber hydrogels for sustained anticancer drug deliveryACS Appl Mater Interfaces2016827171181712627315327
  • CoburnJHarrisJZakharovADImplantable chemotherapy-loaded silk protein materials for neuroblastoma treatmentInt J Cancer2017140372673527770551
  • TianYJiangXChenXShaoZYangWDoxorubicin-loaded magnetic silk fibroin nanoparticles for targeted therapy of multidrug-resistant cancerAdv Mater201426437393739825238148
  • QuJLiuYYuYSilk fibroin nanoparticles prepared by electro-spray as controlled release carriers of cisplatinMater Sci Eng C Mater Biol Appl20144416617425280693
  • LiHTianJWuASelf-assembled silk fibroin nanoparticles loaded with binary drugs in the treatment of breast carcinomaInt J Nanomedicine2016114373438027621628
  • XieMFanDChenYAn implantable and controlled drug-release silk fibroin nanofibrous matrix to advance the treatment of solid tumour cancersBiomaterials2016103334327376557
  • LerdchaiKKitsongsermthonJRatanavarapornJKanokpanontSDamrongsakkulSThai silk fibroin/gelatin sponges for the dual controlled release of curcumin and docosahexaenoic acid for anticancer treatmentJ Pharm Sci2016105122123026579620
  • GuziewiczNBestAPerez-RamirezBKaplanDLLyophilized silk fibroin hydrogels for the sustained local delivery of therapeutic monoclonal antibodiesBiomaterials201132102642265021216004
  • GuziewiczNAMassettiAJPerez-RamirezBJKaplanDLMechanisms of monoclonal antibody stabilization and release from silk biomaterialsBiomaterials201334317766777523859659
  • van NeervenSMTiekenMVermeulenLBijlsmaMFBidirectional interconversion of stem and non-stem cancer cell populations: A reassessment of theoretical models for tumor heterogeneityMol Cell Oncol201632e109879127308617